Skip to main content
SSMXF logo

Sysmex Corporation (SSMXF) Stock Price & Analysis

Sysmex Corporation (SSMXF) — price $11.35 (0.00%), as of the Nov 19, 2026 trading session; market cap $6.83B. Expected results Feb 11, 2027.

Educational signal · not a buy or sell recommendation · How to read this

$11.35 $0.00 (0.00%) Market Cap $6.83B

Sysmex Corporation · SSMXF · Healthcare · Medical - Specialties

Headquartered in Kobe, Japan, Sysmex Corporation is a global leader in the creation, production, and distribution of sophisticated diagnostic instruments, chemical reagents, and related software.

Price as of Nov 19, 2026

Key Statistics

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • SI · SHOULDER INNOVATIONS, INC. · 34 /100
  • QTEX · Inspira Technologies Oxy B.H.N. Ltd. · 45 /100
  • ITOC · iTonic Holdings Ltd. · 29 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$11.35
Change on the day0.00%
52-week range$7.97–$12.50
Market capitalisation$6.83B—
Price / earnings (trailing)38.06
Shares traded on the day300
Beta (volatility vs the S&P 500)0.69
Dividends per share (last 12 months)$0.25
Dividend yield (last 12 months)2.17%

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $8.36, high $12, latest $11. 4 reported quarters marked, 3 above and 1 below the recorded estimate. $12 $8.36 high $12 Feb 12, 2026 · Earnings results · reported above the recorded estimate · close $9.881May 14, 2026 · Earnings results · reported below the recorded estimate · close $8.362Aug 7, 2026 · Earnings results · reported above the recorded estimate · close $103Nov 10, 2026 · Earnings results · reported above the recorded estimate · close $114 Oct 17, 2025 Nov 19, 2026 · $11 $11Oct 17, 2025$11Oct 31, 2025$9.99Nov 14, 2025$9.60Nov 28, 2025$9.33Dec 12, 2025$9.88Dec 26, 2025$9.88Jan 9, 2026$9.88Jan 23, 2026$9.88Feb 6, 2026$8.60Feb 20, 2026$9.35Mar 6, 2026$8.43Mar 20, 2026$8.43Apr 2, 2026$8.43Apr 17, 2026$8.43May 1, 2026$8.36May 15, 2026$8.85May 29, 2026$8.85Jun 12, 2026$8.85Jun 26, 2026$8.85Jul 10, 2026$9.65Jul 24, 2026$10Aug 7, 2026$10Aug 21, 2026$12Sep 4, 2026$12Sep 18, 2026$12Oct 2, 2026$11Oct 16, 2026$11Oct 30, 2026$11Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · above the recorded estimate
  • · Earnings results · below the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

Dated events ahead, in order, not to scaleDec 4, 2026, Dividend payment date; Feb 11, 2027, Next results due. Spacing is order only and carries no duration.Nov 19, 20261Dec 4, 20262Feb 11, 2027
  1. Dividend payment dateCompany record
  2. Next results dueProvider estimate
How to read these dates

Events are in date order; the spacing is not a duration scale. Estimated dates can change.

What to watch next

Other perspectives

Council score for Sysmex (SSMXF): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

4 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Moderate
Margin of Safety Undervalued
Profit Margin Neutral
Revenue Growth Moderate
Debt/Equity Moderate
ROE Neutral
Gross Margin Moderate

Read on: Apr 29, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Apr 29, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Sysmex (SSMXF), and what does it report?

Short answer

Headquartered in Kobe, Japan, Sysmex Corporation is a global leader in the creation, production, and distribution of sophisticated diagnostic instruments, chemical reagents, and related software. Healthcare / Medical Specialties SEC filing business address: 120 Broadway, 32ND Floor, NEW York, NY, 10271. It employs 10,861 people and is led by Hisashi Ietsugu. In Q2 FY2027 it reported revenue of ¥143.71B and net income of ¥9.34B. The market values it at $6.83B.

2 · Latest results

What do the latest results show for Sysmex (SSMXF)?

Short answer · as of

The most recent reported quarter, Q2 FY2027, carried revenue of ¥143.71B. Against analyst estimates the company has EPS beat 3 of the last 8 reports.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$903.07M Nov 10, 2026
Latest report · revenue estimate
$861.92M Nov 10, 2026
Latest report · revenue vs estimate
Above estimate Nov 10, 2026
Latest report · EPS vs estimate
Above estimate Nov 10, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Nov 10, 2026$903.07M$861.92M$0.0972$0.0971
Aug 7, 2026$803.51M$720.54M$0.0871$0.0554
May 14, 2026$874.40M$865.49M$0.0179$0.0374
Feb 12, 2026$820.86M$823.44M$0.1503$0.1394
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2027¥143.71B¥9.34B¥15.47 (diluted)
Q1 FY2027¥129.73B¥8.63B¥14.06 (diluted)
Q4 FY2026¥139.71B¥1.77B¥2.86 (diluted)
Q3 FY2026¥128.75B¥14.69B¥23.53 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Sysmex (SSMXF)?

Short answer · as of

The distress and quality screens read Altman Z 4.85 · Piotroski F 6. Trailing ratios: ROE 7.0% · ROA 4.7% · current ratio 3.40 · earnings yield 2.7% · free-cash-flow yield 5.6%.

Data-derived red flags

  • Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.
  • Rich valuation — a P/E of 38.06 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.
4 · What to check next?

What should you watch next at Sysmex (SSMXF)?

Short answer · as of

The next earnings report is expected on Feb 11, 2027.

What the records here don't tell us

  • Detailed statement figures are not shown because their conversion to USD has not been verified.
  • No insider Form 4 transaction falls inside the window this page reads.
  • Fewer than two score snapshots exist, so no score trend is shown.

Checked against the records this page reads, on the dates shown above.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held SSMXF in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported SSMXF in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

Sysmex Healthcare Stock: Key Questions Answered

These answers are editorial: 1 of these 8 answers is drawn from the SSMXF research dossier (written Mar 17, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.

Is SSMXF a good stock to buy?

Stock Expert AI does not rate SSMXF buy, sell or hold. Sysmex Corporation has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the SSMXF stock price today?

The last price recorded for Sysmex Corporation (SSMXF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What does Sysmex Corporation do?

Sysmex Corporation is a global leader in the development, manufacture, and sale of diagnostic instruments, reagents, and software for the healthcare industry.

What are the key factors to evaluate for SSMXF?

Evaluate SSMXF on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. Digital Medicine Solutions: Sysmex is involved in the development, operation, and maintenance of IT solutions, platforms, and applications related to digital medicine. Not financial advice.

How frequently does SSMXF data refresh on this page?

SSMXF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven SSMXF's recent stock price performance?

Sysmex Corporation (SSMXF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong market position in hematology diagnostics. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider SSMXF overvalued or undervalued right now?

The trailing P/E of Sysmex Corporation (SSMXF) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research SSMXF before investing?

Before investing in Sysmex Corporation (SSMXF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 41 figures on this page — 1 from SEC filings and earnings calls, 31 from Financial Modeling Prep (FMP), 4 with no recorded source, 4 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.